Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 2:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 3,676 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus, Type II Clear all
Completed Phase 2 Interventional Results available

A Study of Single and Multiple Doses of Oral Insulin or Placebo in Subjects With Type 2 Diabetes Mellitus

NCT02954601
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
ORMD-0801 (qd), ORMD-0801 (bid), ORMD-0801 (tid), Placebo
Drug · Other
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
20 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 14, 2026, 2:08 PM EDT
Completed Not applicable Interventional

Insulin Degludec Titration Using Mobile Insulin Dosing System

NCT03091712
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Glooko Mobile Insulin Dosing System(MIDS)
Device
Lead sponsor
Glooko
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Oct 14, 2026, 2:08 PM EDT
Terminated Not applicable Interventional

Developing Affective HeaLth to Improve Adherence to Health Behaviors in Diabetes (DAHLIA II)

NCT04068805
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Happify
Behavioral
Lead sponsor
Happify Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Oct 14, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes

NCT02325466
View directory record Official record
Conditions
Peripheral Artery Disease, Type 2 Diabetes
Interventions
Aspirin, Ticagrelor, Aspirin Placebo, Ticagrelor Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Oct 14, 2026, 2:08 PM EDT
Completed No phase listed Observational

Postpartum Glucose Tolerance With Levonorgesterel IUD Use in Women With Recent Gestational Diabetes

NCT01022645
View directory record Official record
Conditions
Gestational Diabetes, Glucose Intolerance, Type 2 Diabetes, Intrauterine Contraception
Interventions
Mirena (Levonorgestrel IUD), Paragard (Copper IUD ) or Tubal Ligation
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Oct 14, 2026, 2:08 PM EDT
Completed Not applicable Interventional

The Effect of Exercise Training Intensity in Patients With Type 2 Diabetes

NCT01417845
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
High Intensity Exercise Training, Moderate Intensity Exercise Training
Behavioral
Lead sponsor
University of Central Arkansas
Other
Eligibility
18 Years to 69 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Conway, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 14, 2026, 2:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum

NCT05219994
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Hyperoxia Exposure, Normoxia Exposure
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 14, 2026, 2:08 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome

NCT07219602
View directory record Official record
Conditions
Lipidemia, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS)
Interventions
obicetrapib 10 mg + ezetimibe 10 mg FDC daily, Obicetrapib 10 mg, Placebo
Drug · Other
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
32
States / cities
Sun City West, Arizona • La Jolla, California • Pomona, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 14, 2026, 2:08 PM EDT
Completed Not applicable Interventional Results available

TEEN HEED: An Adolescent Diabetes Prevention Intervention Incorporating Novel Mobile Health Technologies

NCT05560386
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Text messaging, Virtual workshop
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
13 Years to 19 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2023 · Synced Oct 14, 2026, 2:08 PM EDT
Withdrawn Phase 3 Interventional

A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 Diabetes

NCT01455922
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ITCA 650, glimepiride
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Hayward, California
Source: ClinicalTrials.gov public record
Updated Dec 25, 2012 · Synced Oct 14, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Enhancement of Cerebral Vasoreactivity and Cognition by Intranasal Insulin in Type 2 Diabetes

NCT01206322
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Intranasal insulin, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
50 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 14, 2026, 2:08 PM EDT
Completed Not applicable Interventional

Treating Type 2 Diabetes by Reducing Postprandial Glucose Elevations: A Paradigm Shift in Lifestyle Modification

NCT03196895
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Weight reduction training, PPG training, discrete BG feedback, continuous BG feedback
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 80 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 14, 2026, 2:08 PM EDT
Terminated Phase 2 Interventional

CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients

NCT04906213
View directory record Official record
Conditions
Kidney Transplant; Complications, Diabetes Mellitus, Type 2
Interventions
Empagliflozin10Mg Tab, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 14, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes

NCT01392573
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutide, insulin degludec
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
58
States / cities
Huntsville, Alabama • Vestavia Hills, Alabama • Anaheim, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Oct 14, 2026, 2:08 PM EDT
Completed Not applicable Interventional Results available

Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine

NCT01089569
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Exenatide, Insulin Glargine
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 14, 2026, 2:08 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

The Role of Hepatic Denervation in the Dysregulation of Glucose Metabolism in Liver Transplant Recipients

NCT03685773
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Glucose, High Blood, Glucose Metabolism Disorders
Interventions
Diazoxide, Placebo (for diazoxide), Nicotinic acid
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
21 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 14, 2026, 2:08 PM EDT
Terminated Phase 4 Interventional Results available

An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects

NCT02793154
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Exenatide, Albiglutide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Louisville, Kentucky • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 14, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents

NCT03285594
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin, Insulin glargine (HOE901), Placebo, Oral Antidiabetes Drugs (OADs)
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Mesa, Arizona • Phoenix, Arizona • Huntington Park, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 14, 2026, 2:08 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Determination of Safety,Tolerability,Pharmacokinetics,Food Effect& Pharmacodynamics of Single & Multiple Doses of P11187

NCT01874366
View directory record Official record
Conditions
Overweight, Diabetes Mellitus Type 2 in Obese
Interventions
P11187, Placebo
Drug
Lead sponsor
Piramal Enterprises Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Oct 14, 2026, 2:08 PM EDT
Completed Phase 2 Interventional

Preventing Medication Mismanagement in People Living With Dementia Through Automated Medication Dispensing With Facial Recognition and Video Observation

NCT06691256
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Medication Adherence, Type 2 Diabetes Mellitus (T2DM)
Interventions
HiDO-ALZ
Device
Lead sponsor
HiDO Technologies
Industry
Eligibility
65 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 14, 2026, 2:08 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%)

NCT00728351
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
vildagliptin + metformin, metformin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 78 Years
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
16
States / cities
Pine Bluff, Arkansas • Long Beach, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 14, 2026, 2:08 PM EDT
Completed Phase 4 Interventional

Effect Of Carvedilol Versus Metoprolol On Glycemic Control In Patients With Type II Diabetes And Hypertension

NCT00060931
View directory record Official record
Conditions
Hypertension
Interventions
carvedilol, metoprolol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 80 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
119
States / cities
Birmingham, Alabama • Columbia, Alabama • Mobile, Alabama + 97 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Oct 14, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Results available

A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients

NCT01280695
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, MSDC-0602 100 mg, MSDC-0602 250 mg, Pioglitazone
Drug
Lead sponsor
Metabolic Solutions Development Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
14
States / cities
Goodyear, Arizona • Chula Vista, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Oct 14, 2026, 2:08 PM EDT
Recruiting Not applicable Interventional

Balance4Mobility: Effects of Walkasins Use in Individuals With Peripheral Neuropathy and Balance Problems

NCT06959277
View directory record Official record
Conditions
Peripheral Neuropathies, Peripheral Neuropathy Due to Chemotherapy, Peripheral Neuropathy With Type 2 Diabetes, Balance Control in Elderly, Gait Disorders
Interventions
Walkasins, Fall Prevention Training
Device · Other
Lead sponsor
RxFunction Inc.
Industry
Eligibility
55 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Mesa, Arizona • Boston, Massachusetts • Saint Paul, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 14, 2026, 2:08 PM EDT